To acknowledge Worldwide Group B Strep Consciousness Month in July, we had a dialog with MinervaX CEO, Per Fischer.
MinervaX is a privately-held Danish biotechnology firm growing a novel prophylactic vaccine towards Group B streptococcus (GBS), with two section II medical trials ongoing in pregnant girls and a section I medical trial ongoing in older adults.
As a result of world burden and no present mechanism for stopping this invasive GBS illness out there. There’s an pressing want for a vaccine to forestall GBS which has a well-recognized morbidity and mortality price.
MinervaX’s GBS vaccine has been granted Quick Observe regulatory standing by the US Meals and Drug Administration. The method is designed to facilitate the event of investigational remedies that exhibit the potential to handle unmet medical wants in critical or life-threatening circumstances.
This follows the European Medicines Company’s resolution to award Precedence Drugs (PRIME) standing to the vaccine.
